| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1734-1140(11)70586-2 |
| P698 | PubMed publication ID | 21857085 |
| P50 | author | Jerzy Chudek | Q47190693 |
| Jan Szewieczek | Q56506213 | ||
| Michał Holecki | Q61786293 | ||
| P2860 | cites work | Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry | Q28194991 |
| A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease | Q28200844 | ||
| GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction | Q29041524 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall | Q30449820 | ||
| Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). | Q31956512 | ||
| Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. | Q32055028 | ||
| Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 | ||
| Effect of ramipril on the incidence of diabetes | Q33999592 | ||
| Effect of luminal angiotensin II receptor antagonists on proximal tubule transport | Q34044156 | ||
| Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial | Q34366640 | ||
| Vascular remodeling: the role of angiotensin-converting enzyme inhibitors | Q34458849 | ||
| Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 | ||
| ACE inhibition and atherogenesis | Q34652136 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group | Q34718800 | ||
| The intracellular renin-angiotensin system: implications in cardiovascular remodeling | Q34750404 | ||
| Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications | Q35158419 | ||
| Endothelial dysfunction: clinical strategies for treating oxidant stress | Q35188942 | ||
| Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure | Q35607233 | ||
| The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials | Q36462791 | ||
| A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction | Q36531143 | ||
| Antihypertensive drugs and fibrinolytic function | Q36680206 | ||
| Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies | Q37601143 | ||
| Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo | Q37772718 | ||
| Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor. | Q40446968 | ||
| Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies | Q40982204 | ||
| Plasma angiotensins in anephric humans: evidence for an extrarenal angiotensin system. | Q41139251 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients | Q44354173 | ||
| Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study | Q44672306 | ||
| Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial | Q44697034 | ||
| ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. | Q45985189 | ||
| Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization? | Q46079855 | ||
| Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. | Q47572885 | ||
| Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor | Q48225244 | ||
| Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure | Q54152720 | ||
| Carotid Intima-Media Thickness and Antihypertensive Treatment | Q57085508 | ||
| Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention | Q57085525 | ||
| Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
| Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. | Q64925074 | ||
| Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa | Q67919989 | ||
| Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies | Q68053927 | ||
| Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators | Q72711428 | ||
| Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators | Q72998299 | ||
| Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans | Q73120262 | ||
| Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans | Q73151526 | ||
| Control of the renal renin system by local factors | Q77295832 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 740-751 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Pharmacological Reports | Q15766499 |
| P1476 | title | Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure--are they important for doctors? | |
| P478 | volume | 63 |
| Q58763326 | ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology |
| Q86109961 | Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure |
| Q36577076 | Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study |
| Q26738584 | Stabilization of high-risk plaques |
Search more.